Treatment Landscape for Myositis: Insights and Innovations

Treating myositis is not like treating most autoimmune diseases. For patients and families first asking what is myositis disease, the answer often arrives years after symptoms have already done their damage. The condition is rare enough that randomized controlled trials are hard to run at scale, which means a lot of clinical decision-making still rests on small studies, case series, and physician experience rather than the kind of evidence base that guides treatment in rheumatoid arthritis or lupus. That gap between what clinicians know and what they can prove shapes almost every aspect of how myositis diagnosis and management proceed.

Corticosteroids are still where myositis treatment starts. High-dose prednisone, typically 1mg per kilogram of body weight per day, remains the standard induction therapy for polymyositis and dermatomyositis despite decades of use and a side effect profile that nobody would describe as acceptable for long-term management. Bone density loss, adrenal suppression, hyperglycemia, infection susceptibility: the list is long, and patients on chronic steroids accumulate these problems over years. The goal has always been to taper as quickly as the disease allows, which in practice means as quickly as the muscle enzymes and clinical symptoms permit, and that varies enormously between patients. Catching myositis symptoms early enough to intervene before significant muscle damage has accumulated is difficult; the proximal weakness tends to be gradual, easy to attribute to deconditioning or stress.

Because steroids alone aren't sufficient for most patients, steroid-sparing immunosuppressants get added early. Methotrexate and azathioprine are the most commonly used, both with decades of data behind them in myositis even if that data is thinner than anyone would like. Mycophenolate mofetil has become increasingly favored, particularly in patients with interstitial lung disease as a complication, where some evidence suggests it may be better tolerated and at least as effective. Choosing between these agents often comes down to a combination of the patient's other conditions, their tolerance for monitoring requirements, and the rheumatologist's clinical experience.

Intravenous immunoglobulin has crossed an important threshold. The ProDERM trial, published in 2021, was the landmark randomized controlled trial that confirmed IVIG produces meaningful functional improvement in dermatomyositis patients who haven't responded adequately to steroids and conventional immunosuppressants. That trial was consequential not just scientifically but regulatorily: the FDA subsequently approved Octagam 10% specifically for adult dermatomyositis, converting what had been off-label practice into a therapy with an explicit indication. Insurance authorization has meaningfully improved as a result, though it hasn't disappeared as a problem entirely. Patients at infusion centers without streamlined prior authorization processes still encounter delays, and access remains uneven across health systems. The approval helped; it did not solve the infrastructure problem.

The JAK inhibitor story has moved faster than most people anticipated. Early case series and small studies suggested tofacitinib and baricitinib could benefit refractory dermatomyositis patients by blocking the interferon signaling pathways that drive inflammation in that subtype, and for several years the field was watching cautiously while larger trials got underway. Those trials have now reported. The Phase 3 VALOR study for brepocitinib, a dual JAK1/TYK2 inhibitor, was the longest and largest placebo-controlled interventional trial ever conducted in dermatomyositis, and its results were sufficiently strong that the FDA accepted the New Drug Application and granted Priority Review in early 2026. Brepocitinib is sitting on the edge of becoming the first targeted oral therapy specifically approved for dermatomyositis. That is not a small development for a disease that has relied on decades-old immunosuppressants and borrowed biologics. The field did not just watch; it arrived somewhere.

Complement inhibition offers a different kind of lesson. The biological logic seemed sound: immune-mediated necrotizing myopathy, driven by anti-HMGCR and anti-SRP antibodies, involves severe complement-mediated myofiber destruction, and zilucoplan, a C5 complement inhibitor, had already shown efficacy in generalized myasthenia gravis through a related mechanism. Trials in necrotizing myopathy proceeded on that basis. They failed. Zilucoplan did not produce meaningful clinical improvement or significant reductions in creatine kinase levels in IMNM patients, and UCB Pharma subsequently halted the development program for myositis entirely. It is a useful reminder that mechanistic plausibility does not equal clinical efficacy, and that rare disease biology has a way of confounding hypotheses that look airtight on paper.

Physical rehabilitation sits alongside pharmacologic treatment rather than after it. The old clinical caution about exercise worsening myositis inflammation has been largely overturned by a body of evidence showing that supervised resistance training during stable disease periods improves strength and function without triggering flares. Getting that message to patients consistently is still a work in progress; some patients arrive at physical therapy years into their diagnosis having been told to rest.

What the treatment landscape for myositis reflects is a field working hard against the constraints of rarity. Small patient populations make trials difficult and slow. In countries like India, where autoimmune diseases frequently go unrecognised at the primary care level and specialist rheumatology access outside major cities remains limited, the gap between trial evidence and patient benefit is even wider. Heterogeneity between subtypes complicates pooling data. Progress is real but uneven: IVIG now has regulatory backing where it once had only clinical consensus, a JAK inhibitor is approaching approval after the largest trial the disease has ever seen, and complement inhibition failed despite having every reason on paper to succeed. That mix of advance and setback, more than any single result, is probably the most accurate picture of where the science stands.